Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infe...

Autores
Parreño, Gladys Viviana; Bai, Muqun; Liu, Fangning; Jing, Jiqiang; Olney, Erika; Li, Guohua; Wen, Ke; Yang, Xingdong; Castellucc, Tammy Bui; Kocher, Jacob F.; Zhou, Xu; Yuan, Lijuan
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
This preclinical study in the gnotobiotic (Gn) pig model of human rotavirus (HRV) infection and disease evaluates the effect of probiotic Lactobacillus rhamnosus GG (LGG) as a mucosal adjuvant on the immunogenicity and cross-protective efficacy of the Lanzhou live oral trivalent (G2, G3, G4) vaccine (TLV, aka LLR3). Gn pigs were immunized with three doses of TLV with or without concurrent administration of nine doses of LGG around the time of the first dose of the TLV vaccination, and were challenged orally with the virulent heterotypic Wa G1P[8] HRV. Three doses of TLV were highly immunogenic and conferred partial protection against the heterotypic HRV infection. LGG significantly enhanced the intestinal and systemic immune responses and improved the effectiveness of protection against the heterotypic HRV challenge-induced diarrhea and virus shedding. In conclusion, we demonstrated the immune-stimulating effects of probiotic LGG as a vaccine adjuvant and generated detailed knowledge regarding the cross-reactive and type-specific antibody and effector B and T cell immune responses induced by the TLV. Due to the low cost, ease of distribution and administration, and favorable safety profiles, LGG as an adjuvant has the potential to play a critical role in improving rotavirus vaccine efficacy and making the vaccines more cost-effective.
Instituto de Virología
Fil: Parreño, Gladys Viviana. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria (INTA). INCUINTA. Instituto de Virologia e Innovaciones Tecnologicas (IVIT); Argentina
Fil: Bai, Muqun. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Bai, Muqun. Lanzhou Institute of Biological Products; China
Fil: Liu, Fangning. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Jing, Jiqiang. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Jing, Jiqiang. Shandong Vocational College of Animal Husbandry and Veterinary Medicine. Department of Animal Medicine; China
Fil: Olney, Erika. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Olney, Erika. Midwestern University. College of Veterinary Medicine; Estados Unidos
Fil: Li, Guohua. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Wen, Ke. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Yang, Xingdong. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Castellucc, Tammy Bui. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Kocher, Jacob F. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Zhou, Xu. Lanzhou Institute of Biological Products; China
Fil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fuente
Vaccines 10 (9) : 1529 (Septiembre 2022)
Materia
Rotavirus
Probiotics
Vaccine Adjuvants
Gnotobiotic Animals
Swine
Probióticos
Coadyuvantes de Vacunas
Animales Notobióticos
Cerdo
Lactobacillus rhamnosus
Infección por Rotavirus Humano
Human Rotavirus Infection
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/16376
Acceder
id INTADig_29a7b9791e31f1e2955f468db3afa158
oai_identifier_str oai:localhost:20.500.12123/16376
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and diseaseParreño, Gladys VivianaBai, MuqunLiu, FangningJing, JiqiangOlney, ErikaLi, GuohuaWen, KeYang, XingdongCastellucc, Tammy BuiKocher, Jacob F.Zhou, XuYuan, LijuanRotavirusProbioticsVaccine AdjuvantsGnotobiotic AnimalsSwineProbióticosCoadyuvantes de VacunasAnimales NotobióticosCerdoLactobacillus rhamnosusInfección por Rotavirus HumanoHuman Rotavirus InfectionThis preclinical study in the gnotobiotic (Gn) pig model of human rotavirus (HRV) infection and disease evaluates the effect of probiotic Lactobacillus rhamnosus GG (LGG) as a mucosal adjuvant on the immunogenicity and cross-protective efficacy of the Lanzhou live oral trivalent (G2, G3, G4) vaccine (TLV, aka LLR3). Gn pigs were immunized with three doses of TLV with or without concurrent administration of nine doses of LGG around the time of the first dose of the TLV vaccination, and were challenged orally with the virulent heterotypic Wa G1P[8] HRV. Three doses of TLV were highly immunogenic and conferred partial protection against the heterotypic HRV infection. LGG significantly enhanced the intestinal and systemic immune responses and improved the effectiveness of protection against the heterotypic HRV challenge-induced diarrhea and virus shedding. In conclusion, we demonstrated the immune-stimulating effects of probiotic LGG as a vaccine adjuvant and generated detailed knowledge regarding the cross-reactive and type-specific antibody and effector B and T cell immune responses induced by the TLV. Due to the low cost, ease of distribution and administration, and favorable safety profiles, LGG as an adjuvant has the potential to play a critical role in improving rotavirus vaccine efficacy and making the vaccines more cost-effective.Instituto de VirologíaFil: Parreño, Gladys Viviana. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria (INTA). INCUINTA. Instituto de Virologia e Innovaciones Tecnologicas (IVIT); ArgentinaFil: Bai, Muqun. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Bai, Muqun. Lanzhou Institute of Biological Products; ChinaFil: Liu, Fangning. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Jing, Jiqiang. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Jing, Jiqiang. Shandong Vocational College of Animal Husbandry and Veterinary Medicine. Department of Animal Medicine; ChinaFil: Olney, Erika. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Olney, Erika. Midwestern University. College of Veterinary Medicine; Estados UnidosFil: Li, Guohua. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Wen, Ke. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Yang, Xingdong. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Castellucc, Tammy Bui. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Kocher, Jacob F. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosFil: Zhou, Xu. Lanzhou Institute of Biological Products; ChinaFil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados UnidosMDPI2023-12-28T10:38:39Z2023-12-28T10:38:39Z2022-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/16376https://www.mdpi.com/2076-393X/10/9/15292076-393Xhttps://doi.org/10.3390/vaccines10091529Vaccines 10 (9) : 1529 (Septiembre 2022)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-04T09:50:09Zoai:localhost:20.500.12123/16376instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-04 09:50:10.185INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
title Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
spellingShingle Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
Parreño, Gladys Viviana
Rotavirus
Probiotics
Vaccine Adjuvants
Gnotobiotic Animals
Swine
Probióticos
Coadyuvantes de Vacunas
Animales Notobióticos
Cerdo
Lactobacillus rhamnosus
Infección por Rotavirus Humano
Human Rotavirus Infection
title_short Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
title_full Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
title_fullStr Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
title_full_unstemmed Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
title_sort Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease
dc.creator.none.fl_str_mv Parreño, Gladys Viviana
Bai, Muqun
Liu, Fangning
Jing, Jiqiang
Olney, Erika
Li, Guohua
Wen, Ke
Yang, Xingdong
Castellucc, Tammy Bui
Kocher, Jacob F.
Zhou, Xu
Yuan, Lijuan
author Parreño, Gladys Viviana
author_facet Parreño, Gladys Viviana
Bai, Muqun
Liu, Fangning
Jing, Jiqiang
Olney, Erika
Li, Guohua
Wen, Ke
Yang, Xingdong
Castellucc, Tammy Bui
Kocher, Jacob F.
Zhou, Xu
Yuan, Lijuan
author_role author
author2 Bai, Muqun
Liu, Fangning
Jing, Jiqiang
Olney, Erika
Li, Guohua
Wen, Ke
Yang, Xingdong
Castellucc, Tammy Bui
Kocher, Jacob F.
Zhou, Xu
Yuan, Lijuan
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Rotavirus
Probiotics
Vaccine Adjuvants
Gnotobiotic Animals
Swine
Probióticos
Coadyuvantes de Vacunas
Animales Notobióticos
Cerdo
Lactobacillus rhamnosus
Infección por Rotavirus Humano
Human Rotavirus Infection
topic Rotavirus
Probiotics
Vaccine Adjuvants
Gnotobiotic Animals
Swine
Probióticos
Coadyuvantes de Vacunas
Animales Notobióticos
Cerdo
Lactobacillus rhamnosus
Infección por Rotavirus Humano
Human Rotavirus Infection
dc.description.none.fl_txt_mv This preclinical study in the gnotobiotic (Gn) pig model of human rotavirus (HRV) infection and disease evaluates the effect of probiotic Lactobacillus rhamnosus GG (LGG) as a mucosal adjuvant on the immunogenicity and cross-protective efficacy of the Lanzhou live oral trivalent (G2, G3, G4) vaccine (TLV, aka LLR3). Gn pigs were immunized with three doses of TLV with or without concurrent administration of nine doses of LGG around the time of the first dose of the TLV vaccination, and were challenged orally with the virulent heterotypic Wa G1P[8] HRV. Three doses of TLV were highly immunogenic and conferred partial protection against the heterotypic HRV infection. LGG significantly enhanced the intestinal and systemic immune responses and improved the effectiveness of protection against the heterotypic HRV challenge-induced diarrhea and virus shedding. In conclusion, we demonstrated the immune-stimulating effects of probiotic LGG as a vaccine adjuvant and generated detailed knowledge regarding the cross-reactive and type-specific antibody and effector B and T cell immune responses induced by the TLV. Due to the low cost, ease of distribution and administration, and favorable safety profiles, LGG as an adjuvant has the potential to play a critical role in improving rotavirus vaccine efficacy and making the vaccines more cost-effective.
Instituto de Virología
Fil: Parreño, Gladys Viviana. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Parreño, Gladys Viviana. Instituto Nacional de Tecnología Agropecuaria (INTA). INCUINTA. Instituto de Virologia e Innovaciones Tecnologicas (IVIT); Argentina
Fil: Bai, Muqun. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Bai, Muqun. Lanzhou Institute of Biological Products; China
Fil: Liu, Fangning. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Jing, Jiqiang. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Jing, Jiqiang. Shandong Vocational College of Animal Husbandry and Veterinary Medicine. Department of Animal Medicine; China
Fil: Olney, Erika. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Olney, Erika. Midwestern University. College of Veterinary Medicine; Estados Unidos
Fil: Li, Guohua. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Wen, Ke. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Yang, Xingdong. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Castellucc, Tammy Bui. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Kocher, Jacob F. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
Fil: Zhou, Xu. Lanzhou Institute of Biological Products; China
Fil: Yuan, Lijuan. Virginia-Maryland College of Veterinary Medicine. Department of Biomedical Sciences and Pathobiology; Estados Unidos
description This preclinical study in the gnotobiotic (Gn) pig model of human rotavirus (HRV) infection and disease evaluates the effect of probiotic Lactobacillus rhamnosus GG (LGG) as a mucosal adjuvant on the immunogenicity and cross-protective efficacy of the Lanzhou live oral trivalent (G2, G3, G4) vaccine (TLV, aka LLR3). Gn pigs were immunized with three doses of TLV with or without concurrent administration of nine doses of LGG around the time of the first dose of the TLV vaccination, and were challenged orally with the virulent heterotypic Wa G1P[8] HRV. Three doses of TLV were highly immunogenic and conferred partial protection against the heterotypic HRV infection. LGG significantly enhanced the intestinal and systemic immune responses and improved the effectiveness of protection against the heterotypic HRV challenge-induced diarrhea and virus shedding. In conclusion, we demonstrated the immune-stimulating effects of probiotic LGG as a vaccine adjuvant and generated detailed knowledge regarding the cross-reactive and type-specific antibody and effector B and T cell immune responses induced by the TLV. Due to the low cost, ease of distribution and administration, and favorable safety profiles, LGG as an adjuvant has the potential to play a critical role in improving rotavirus vaccine efficacy and making the vaccines more cost-effective.
publishDate 2022
dc.date.none.fl_str_mv 2022-09
2023-12-28T10:38:39Z
2023-12-28T10:38:39Z
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/16376
https://www.mdpi.com/2076-393X/10/9/1529
2076-393X
https://doi.org/10.3390/vaccines10091529
url http://hdl.handle.net/20.500.12123/16376
https://www.mdpi.com/2076-393X/10/9/1529
https://doi.org/10.3390/vaccines10091529
identifier_str_mv 2076-393X
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Vaccines 10 (9) : 1529 (Septiembre 2022)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1842341417288990720
score 12.623145

Publicaciones similares